Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Raises Target Price to $7
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20
Checkpoint Therapeutics Analyst Ratings
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20
Checkpoint Therapeutics Analyst Ratings
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20
Optimistic Buy Rating for Checkpoint Therapeutics Driven by Strong Financial Position and Strategic Collaborations
HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $20 Price Target
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20
Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Announces Target Price $4
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Cuts Target Price to $20
Checkpoint Therapeutics Analyst Ratings
Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating
Lake Street Remains a Buy on Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Checkpoint Therapeutics (CKPT), Mediwound (MDWD)
Lake Street Sticks to Its Buy Rating for Checkpoint Therapeutics (CKPT)
HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target
Checkpoint Therapeutics Analyst Ratings
HC Wainwright & Co. : Checkpoint Therapeutics (CKPT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $34.00.